Structure Therapeutics (GPCR) Receivables - Other (2025 - 2026)
Structure Therapeutics (GPCR) posted quarterly Receivables - Other of -$100.0 million for Q1 2026, down 200.0% quarter-over-quarter from $100.0 million in Q4 2025.
Powered by 
Analysis
Structure Therapeutics (GPCR) Receivables - Other (2025 - 2026) Analysis & Trends
Structure Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at -$100.0 million for Q1 2026.
- In Q1 2026, Receivables - Other changed N/A year-over-year to -$100.0 million; the TTM figure through Dec 2025 stood at $100.0 million (changed N/A YoY), while the FY2025 annual figure was $100.0 million, changed N/A from the prior year.
- Receivables - Other for Q1 2026 stood at -$100.0 million, down from $100.0 million in the prior quarter.
- The five-year high for Receivables - Other was $100.0 million in Q4 2025, with the low at -$100.0 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Structure Therapeutics | 10.32 Bn | 10.32 Bn | - |